Video

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

The high-risk period for regrowth of the tumor is the first 18 months following treatment, Paty explains. In this window, most practitioners who are conducting the "watch-and-wait" approach are doing so with patients in 3- to 4-month intervals. This would include a digital exam with a flexible fiberoptic sigmoidoscopy, careful examination of the rectum and tumor bed, and any scarring. The clinical examination is supplemented by cross-sectional imaging. High-resolution MRI is the optimal technique to use, especially when assessing the lymph nodes.

After the 2-year period, the risk of local cancer regrowth drops significantly, he adds, and patients are then examined at 6-month intervals. Currently, most researchers believe that patients should continue to be assessed annually for the remainder of their lives.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD